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1. INTRODUCTION {#ane12812-sec-0005}
===============

Cognitive decline affects the majority of patients with idiopathic Parkinson\'s disease (PD) and has a major impact on quality of life[1](#ane12812-bib-0001){ref-type="ref"} and morbidity,[2](#ane12812-bib-0002){ref-type="ref"} but the phenotype, pathophysiology, and genetics of the condition are incompletely understood.

Genetic factors are likely to contribute to cognitive dysfunction in PD, as reported in a small number of studies.[3](#ane12812-bib-0003){ref-type="ref"}, [4](#ane12812-bib-0004){ref-type="ref"}, [5](#ane12812-bib-0005){ref-type="ref"}, [6](#ane12812-bib-0006){ref-type="ref"} A functional Catechol‐O‐methyltransferase (*COMT*) gene polymorphism (Val^158^Met; rs4680) results in a COMT enzyme with reduced dopamine degradation activity. Human carriers of two *COMT* ^158^Met‐alleles (^158^Met homozygotes) show about 40% lower enzymatic activity in the brain compared to ^158^Val homozygotes,[7](#ane12812-bib-0007){ref-type="ref"} and higher prefrontal dopamine activation as measured by PET.[8](#ane12812-bib-0008){ref-type="ref"} The *COMT* ^158^Val‐allele correlates with lower scores in tests of working memory in healthy volunteers (showing complex relations to the same functions in PD), and with gray matter atrophy in dopamine‐innervated brain areas in patients with dementia disorders.[9](#ane12812-bib-0009){ref-type="ref"}

Also affecting dopamine transmission, the C^957^T polymorphism of the Dopamine Receptor D2 (*DRD2*) gene (rs6277) affects messenger RNA stability,[10](#ane12812-bib-0010){ref-type="ref"} thereby influencing the level of expression of D2 receptors in the brain. The ^957^C/C genotype correlates with higher D2 receptor densities in extrastriatal, thalamic and neocortical areas,[11](#ane12812-bib-0011){ref-type="ref"} and better episodic memory in healthy elders.[12](#ane12812-bib-0012){ref-type="ref"} Hypofunction of extrastriatal dopamine receptor D2 subsystems, including in the insula, was recently found to contribute to cognitive decline in PD.[13](#ane12812-bib-0013){ref-type="ref"}, [14](#ane12812-bib-0014){ref-type="ref"}

Variability in genes related to dopamine transmission can potentially clarify the role of dopamine deficiency in relation to cognitive decline in PD. Therefore, we investigated the above‐mentioned polymorphisms and cognitive functions in prospectively followed patients with PD. As a measurement of structural integrity, we included a sensitive CSF biomarker for neurodegeneration of myelinated axons (neurofilament light chain; NFL).[15](#ane12812-bib-0015){ref-type="ref"}

2. MATERIALS AND METHODS {#ane12812-sec-0006}
========================

2.1. Participants {#ane12812-sec-0007}
-----------------

All patients with PD participated in a prospective, population‐based incidence study of unselected cases of new‐onset idiopathic parkinsonism, from a geographically defined area in Sweden. The study design has been described previously in detail.[16](#ane12812-bib-0016){ref-type="ref"} In brief, inclusion lasted from January 1, 2004, through April 30, 2009. Patients were followed by a movement disorder team at a University hospital, representing the only neurology clinic in the region. Patients with secondary parkinsonism (eg, drug induced parkinsonism) or dementia at baseline were excluded. Of 182 enrolled in the study, 144 patients of European ancestry were diagnosed as having PD, and of these, samples for *COMT* Val^158^Met and *DRD2* C^957^T genotyping were collected from 134 (Figure [1](#ane12812-fig-0001){ref-type="fig"}). The patients with PD who did not provide samples for genotyping (n = 10) were older than the others (82.3 vs 70.4 years) and had lower Mini‐Mental State Examination (MMSE) scores, but were otherwise comparable. All patients were followed with standardized clinical examinations, including MMSE and motor assessments at least yearly for 6‐10 years, except 14 non‐demented patients that died and were followed shorter. A diagnosis of PD required two examiners (neurologists specialized in movement disorders) to agree that the clinical criteria for the diagnosis were fulfilled according to the UK Parkinson\'s Disease Society Brain Bank criteria (UK PDSBB).[17](#ane12812-bib-0017){ref-type="ref"} Having a family member with PD was not, however, treated as an exclusion criterium. All except three of the 134 patients with PD were examined with FP‐CIT SPECT (DAT‐scan), and all had pathological uptake. In three of the PD cases, the diagnosis was confirmed by autopsy. For comparison, *COMT* Val^158^Met and *DRD2* C^957^T genotype and cognitive function in 30 adults, demographically similar, neurologically healthy controls with normal FP‐CIT uptake on SPECT, were also determined. All participants provided written informed consent. The study was approved by the Regional Medical Ethics Board in Umeå, Sweden, and was performed in accordance with the Declaration of Helsinki.

![Flow of Parkinson\'s disease patients through the 10‐year study period. PD, Parkinson\'s disease; UK PDSBB,UK Parkinson\'s Disease Society Brain Bank](ANE-137-91-g001){#ane12812-fig-0001}

2.2. Genotyping and cerebrospinal fluid analysis {#ane12812-sec-0008}
------------------------------------------------

DNA was isolated from peripheral blood, using standard procedures. The polymorphisms of interest in the *COMT* and *DRD2* genes, rs4680 and rs6277, were genotyped using TaqMan Assay‐by‐design (Applied Biosystems, Foster City, CA, USA). The assay was performed according to manufacturer\'s instructions, and genotypes were analyzed using the allelic discrimination function of the TaqMan 7900 HT Fast Real‐Time PCR system (Applied Biosystems, Foster City, CA, USA); 10% of the samples were run in duplicate, with 100% concordance. Genotype success rates of 98.3% (rs4680) and 100.0% (rs6277) were obtained. 103 of the patients with PD agreed to cerebrospinal fluid (CSF) collection by lumbar puncture at baseline, 1 year and/or 3 years. NFL concentration in CSF was measured with an ELISA method (NF‐light^®^ ELISA kit, UmanDiagnostics AB, Umeå, Sweden) as described by the manufacturer by board‐certified laboratory technicians. The laboratory analyses were performed blinded from clinical data.

2.3. Cognitive impairment {#ane12812-sec-0009}
-------------------------

Extensive neuropsychological testing, covering specific cognitive domains and used for PD‐mild cognitive impairment (MCI) and PD dementia (PDD) diagnostics, was performed at 0, 1, 3, 5, and 8 years.[18](#ane12812-bib-0018){ref-type="ref"} MCI was diagnosed according to Movement Disorder Society criteria.[19](#ane12812-bib-0019){ref-type="ref"} As the protocol included two tests of all cognitive domains but language, MCI was diagnosed on modified level 2 criteria, in keeping with previous research.[20](#ane12812-bib-0020){ref-type="ref"} See Table [1](#ane12812-tbl-0001){ref-type="table-wrap"} for tests used for MCI classification, the partition of the tests and criteria for PDD diagnoses. Structural MRI and routine laboratory tests were performed in all patients to exclude non‐PDD causes of dementia. Diagnoses of PDD were determined by neurologists experienced in neurodegenerative disorders, blinded to the genotype of the patient. No patient with PD had the onset of dementia ≤1 year following motor onset (as in Lewy body dementia). All demented patients had PDD, according to published criteria.[21](#ane12812-bib-0021){ref-type="ref"}

###### 

Tests used for Parkinson\'s disease cognitive impairment classification

  -------------------------------------------------------------------------------------------------------------------------------------------------------
  Neuropsychological function   Test
  ----------------------------- -------------------------------------------------------------------------------------------------------------------------
  Episodic memory               Free and Cued Selective Reminding Test (FCSRT)[a](#ane12812-note-0002){ref-type="fn"}\
                                Logical memory and Paired associative learning from Wechsler memory scale (WMS)[a](#ane12812-note-0002){ref-type="fn"}\
                                Brief visuospatial memory test (BVMT) total recall[a](#ane12812-note-0002){ref-type="fn"}

  Working memory                Digit span forward, from Wechsler Adult Intelligence Scale (WAIS) III[b](#ane12812-note-0002){ref-type="fn"}\
                                Digit span backwards, from Wechsler Adult Intelligence Scale (WAIS) III[b](#ane12812-note-0002){ref-type="fn"}

  Attention                     Trail Making Test (TMT) A[c](#ane12812-note-0002){ref-type="fn"} and B[c](#ane12812-note-0002){ref-type="fn"}

  Verbal function               Controlled Oral Word Association (COWA)\
                                Boston Naming Test (BNT)

  Visuospatial function         The Benton Judgement of Line Orientation test[d](#ane12812-note-0002){ref-type="fn"}\
                                Pentagon copying from Mini‐Mental State Examination (MMSE)

  Executive function            Wisconsin card sorting test (WCST) -- computer version 2[e](#ane12812-note-0002){ref-type="fn"}\
                                Mental Control from Wechsler memory scale (WMS)\
                                Category fluency (animals in 60 seconds)[e](#ane12812-note-0002){ref-type="fn"}
  -------------------------------------------------------------------------------------------------------------------------------------------------------

A domain score was calculated by the mean of standardized scores (Z‐scores) in the tests of episodic memory^a^, working memory^b^, attention^c^, visuospatial function^d^, and executive function^e^.

Subjects were classified as having mild cognitive impairment (PD‐MCI) if: (i) impaired in a minimum of two tests in one domain (single domain MCI) or in a minimum of one test in two different domains (multiple domain MCI), (ii) impairments were ≥1.5 standard deviations below mean of normative data, (iii) self‐perceived cognitive decline was reported by Questionnaire and/or directly by patient and/or family member, and (iv) no functional impairment in basic activities of living.

Parkinson\'s disease dementia (PDD) diagnoses were based on neuropsychological test results, objective and subjective cognitive decline, and by the occurrence of functional impairment in basic activities of living (ie, driving a car, social or personal care, medication management) due to cognitive decline.
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2.4. Statistical analyses {#ane12812-sec-0010}
-------------------------

Baseline differences in demographic, cognitive, and CSF variables between different *COMT* and *DRD2* genotype groups were tested by Kruskal‐Wallis tests, ANOVA, and Fisher\'s exact test, as appropriate. Based on previous research, *a priori* hypothesized risk genotypes (*COMT* ^158^Val/Val and *DRD2* ^957^T/T) were compared with other genotypes, using Kaplan‐Meier plots to investigate PD‐MCI and PDD incidence. To allow for correction for age, sex, disease duration, and cognitive status at baseline, hazard ratios were estimated by Cox proportional hazards regression models. Proportionality of hazards was evaluated by log‐log methods. To investigate potential domain‐specific effects, neuropsychological test scores were merged into six domains (episodic memory, working memory, attention, executive function, visuospatial function, and language), following the partition suggested by the Movement Disorder Society (see Table [1](#ane12812-tbl-0001){ref-type="table-wrap"}).[19](#ane12812-bib-0019){ref-type="ref"} The domain scores (measured by average standard deviations above or below the score mean at baseline; ie, Z‐score) in five domains, throughout the study period, and CSF NFL concentrations (tested at 0, 1, and 3 years), were compared in the genotype groups by linear mixed models, run with and without adjustment (see Table [4](#ane12812-tbl-0004){ref-type="table-wrap"}). The use of mixed‐effects models accounts for variability in length of follow‐up and is flexible with missing data. Although used in MCI diagnostics, language was excluded from mixed model analyses because of non‐normal distribution of scores. Differences in episodic memory (if found) were further analyzed in free‐ and cued recall conditions. *P* \< .05 was considered significant. Holm‐Bonferroni correction for multiple comparisons was made in the Cox regression models and the mixed model analyses (see Tables [3](#ane12812-tbl-0003){ref-type="table-wrap"} and [4](#ane12812-tbl-0004){ref-type="table-wrap"}). All statistical analyses were performed using a software program (SPSS 23.0; SPSS Inc).

3. RESULTS {#ane12812-sec-0011}
==========

*COMT* Val^158^Met genotype was successfully determined in 132 of the patients with PD who donated samples and *DRD2* C^957^T genotype in 134 (all) of the patients with PD who donated samples. The genotypes had relatively even distributions among the participants. At baseline, there were no major differences in clinical characteristics or NFL concentrations in the different *COMT* and *DRD2* genotype groups (Table [2](#ane12812-tbl-0002){ref-type="table-wrap"}); 54 (40.3%) of the patients with PD had MCI at baseline. During follow‐up, 50 patients (37.3%) developed PDD, and 28 patients (20,9%) converted from PD‐normal to MCI. The genotyped patients had a median follow‐up of 7.0 years (interquartile range: 6.0‐9.0 years). There were no significant differences in medication dosages between the genotype groups during follow‐up, as measured by mean levodopa equivalent dose scores. In the healthy control group, 25 participants carried *COMT* ^158^Met‐alleles and 19 participants carried *DRD2* ^957^C‐alleles.

###### 

Baseline characteristics of 134 Parkinson\'s disease patients in relation to *COMT* Val^158^Met‐ and *DRD2* C^957^T genotype

  Variable                                                       *COMT* ^158^Met/Met genotype (n = 42)   *COMT* ^158^Val/Met genotype (n = 64)   *COMT* ^158^Val/Val genotype (n = 26)   *P*‐value
  -------------------------------------------------------------- --------------------------------------- --------------------------------------- --------------------------------------- -----------
  Age                                                            70.3 (9.0)                              69.3 (10.3)                             72.9 (9.1)                              .273
  Disease duration in months, median (IQR)                       25.4 (12.6‐36.1)                        13.4 (8.1‐24.4)                         16.9 (10.0‐35.3)                        .042
  Sex, M:F (% male)                                              23:19 (54.8%)                           41:23 (64.1%)                           15:11 (57.7%)                           .614
  UPDRS III, median (IQR)                                        26 (13‐36)                              25 (18‐34)                              29 (24‐37)                              .340
  MMSE                                                           28.6 (1.4)                              28.7 (1.4)                              28.7 (1.3)                              .959
  CSF NFL concentration, ng/L, \[number with baseline sample\]   1247 (760) \[32\]                       1499 (1601) \[45\]                      1508 (738) \[18\]                       .638

  Variable                                                       DRD2 ^957^C/C genotype (n = 31)   DRD2 ^957^T/C genotype (n = 66)   DRD2 ^957^T/T genotype (n = 37)   *P*‐value
  -------------------------------------------------------------- --------------------------------- --------------------------------- --------------------------------- -----------
  Age                                                            71.9 (9.7)                        69.1 (10.2)                       71.5 (9.3)                        .286
  Disease duration in months, median (IQR)                       24.0 (10.2‐41.0)                  12.7 (8.0‐30.0)                   20.6 (12.2‐31.0)                  .138
  Sex, M:F (% male)                                              18:13 (58.1%)                     40:26 (60.6%)                     22:15 (59.5%)                     .971
  UPDRS III, median (IQR)                                        28 (21‐35)                        23 (16‐31)                        26 (19‐39)                        .166
  MMSE                                                           28.5 (1.6)                        28.8 (1.3)                        28.4 (1.6)                        .377
  CSF NFL concentration, ng/L, \[number with baseline sample\]   1465 (762) \[23\]                 1269 (848) \[50\]                 1762 (1928) \[27\]                .247

Values are expressed as means (standard deviation) unless otherwise stated. Disease duration was defined by time from onset of first motor symptom to diagnosis of PD. COMT, catechol‐O‐methyltransferase; DRD2, dopamine receptor D2; PD, Parkinson\'s disease; IQR, interquartile range; UPDRS III, Unified Parkinson\'s Disease Rating Scale, part III (motor function); MMSE, Mini‐Mental State Examination; CSF, cerebrospinal fluid; NFL, neurofilament light chain protein.
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3.1. *COMT* genotype in PD {#ane12812-sec-0012}
--------------------------

As shown in Figure [2](#ane12812-fig-0002){ref-type="fig"}A, the *COMT* ^158^Val/Val genotype increased the risk of any cognitive decline in PD during follow‐up (decline from PD‐normal to PD‐MCI or from PD‐MCI to PDD, *P* = .006). However, as shown by Cox regression (Table [3](#ane12812-tbl-0003){ref-type="table-wrap"}) and in Figure [2](#ane12812-fig-0002){ref-type="fig"}B, the increased risk of cognitive decline was driven by a higher incidence of PD‐MCI among carriers of two *COMT* ^158^Val alleles (*COMT* ^158^Val/Val homozygotes). The *COMT* ^158^Val/Val homozygotes had 2.1 times higher hazard for developing PD‐MCI compared to PD patients with other *COMT* ^158^ genotypes, after correction for age, sex, disease duration, and baseline cognitive status (*P* = .023), but the *COMT* ^158^Val/Val genotype was not a risk factor for PDD. Analyses of survival times with no cognitive impairment showed that the increased risk of cognitive decline in *COMT* ^158^Val/Val carriers occurred between baseline and the fifth year of follow‐up. There was no measurable effect related to *COMT* genotype in the analysis of single cognitive domains (estimated by linear Mixed Models). The concentration of NFL in cerebrospinal fluid (CSF) did not significantly differ between the different *COMT* genotype groups. The *COMT* genotype had no effects on cognitive functions in the healthy controls (data not shown).

![Effect of the *COMT* Val^158^Met and *DRD2* C^957^T genotypes on cognitive decline in Parkinson\'s disease. Kaplan‐Meier plots showing the incidence of cognitive decline in relation to *COMT* (A--C) and *DRD2* (D--F) genotype. The specific incidence of PD‐MCI and PDD (B, C, E, and F) is shown here only for the patients who had a normal cognitive function at baseline (n = 80). PD, Parkinson\'s disease; COMT, catechol‐O‐methyltransferase; DRD2, dopamine receptor D2; MCI, mild cognitive impairment; PDD, Parkinson\'s disease dementia](ANE-137-91-g002){#ane12812-fig-0002}

###### 

Cognitive decline in 134 Parkinson\'s disease patients, in relation to *COMT* Val^158^Met‐ and *DRD2* C^957^T genotype

                                                                H.R. (95% CI)      *P*‐value
  ------------------------------------------------------------- ------------------ -----------------------------------------------
  **Any cognitive decline (MCI or PDD)**                                           
  ↑No. of *COMT* ^158^Val‐alleles                               1.51 (1.11‐2.06)   .009[a](#ane12812-note-0007){ref-type="fn"}
  ↑No. of *DRD2* ^957^T‐alleles                                 1.64 (1.17‐2.31)   .004[a](#ane12812-note-0007){ref-type="fn"}
  *COMT* ^158^Val/Val vs. any Met allele                        1.79 (1.06‐3.03)   .030[a](#ane12812-note-0007){ref-type="fn"}
  *DRD2* ^957^T/T vs. any C allele                              2.31 (1.41‐3.79)   \<.001[a](#ane12812-note-0007){ref-type="fn"}
  *COMT* ^158^Val/Val or *DRD2* ^957^T/T                        2.46 (1.54‐3.91)   \<.001[a](#ane12812-note-0007){ref-type="fn"}
  **MCI development** [b](#ane12812-note-0008){ref-type="fn"}                      
  *COMT* ^158^Val/Val vs. any Met allele                        2.13 (1.11‐4.08)   .023[a](#ane12812-note-0007){ref-type="fn"}
  *DRD2* ^957^T/T vs. any C allele                              2.12 (1.14‐3.94)   .018[a](#ane12812-note-0007){ref-type="fn"}
  **PDD development**                                                              
  *COMT* ^158^Val/Val vs. any Met allele                        1.11 (0.51‐2.45)   .791
  *DRD2* ^957^T/T vs. any C allele                              3.22 (1.64‐6.30)   \<.001[a](#ane12812-note-0007){ref-type="fn"}

Hazard Ratios (H.R.) are for risks within 6‐10 years, after correction for age, disease duration, sex, and baseline cognitive status (normal or MCI).

Significant (*P* \< 0.05) after Holm‐Bonferroni correction.

Risk of PD‐MCI was analyzed in the 80 patients who had normal cognition at baseline, while the other outcomes were analyzed in all patients.

COMT, catechol‐O‐methyltransferase; DRD2, dopamine receptor D2; MCI, mild cognitive impairment; PDD, Parkinson\'s disease dementia; ↑, higher number (0, 1, or 2).
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3.2. *DRD2* genotype in PD {#ane12812-sec-0013}
--------------------------

As shown in Figure [2](#ane12812-fig-0002){ref-type="fig"}D, the *DRD2* ^957^T/T genotype increased the risk of any cognitive decline in PD, measured by incidence of either PD‐MCI or PDD (*P* = .002). More specifically, carrying a *DRD2* ^957^T/T genotype increased the hazard for developing PDD 3.2 times, in comparison with PD patients with other *DRD2* genotypes (*P* \< .001; Table [3](#ane12812-tbl-0003){ref-type="table-wrap"}), after correction for age, sex, disease duration, and baseline cognitive status. The ^957^T/T genotype was also a risk factor for PD‐MCI development among patients with normal cognition at baseline (n = 80, *P* = .018, Table [3](#ane12812-tbl-0003){ref-type="table-wrap"}). Conversely, carriers of any *DRD2* ^957^C alleles had a lower risk of all types of cognitive decline (Figure [2](#ane12812-fig-0002){ref-type="fig"}FD‐; Table [3](#ane12812-tbl-0003){ref-type="table-wrap"}). Analysis of test scores in specific cognitive domains showed that carriers of the *DRD2* ^957^T/T genotype had significantly poorer performances in episodic memory (on average 0.25 standard deviations lower scores, *P* = .007) and in attention (on average 0.58 standard deviations lower scores, *P* \< .001) after correction for confounding factors (Table [4](#ane12812-tbl-0004){ref-type="table-wrap"}). Patients with PD with a *DRD2* ^957^T/T genotype tended to perform slightly worse in all domains, but apart from the differences in episodic memory and attention, effects were non‐significant after correction for multiple comparisons. Detailed analysis of episodic memory showed opposite effects of *DRD2* genotype in free versus cued recall. While PD patients with the *DRD2* ^957^T/T genotype had a significantly poorer performance in free recall (*P* = .021), they performed better in cued recall (*P* = .026). NFL concentrations in CSF did not differ between the *DRD2* genotypes.

###### 

Longitudinal cognitive function and cerebrospinal fluid data in 134 Parkinson\'s disease patients, in relation to *COMT* Val^158^Met‐ and *DRD2* C^957^T genotype

  Cognitive domain                                  Mean difference, measured in SDs (95% CI)   *P*‐value
  ------------------------------------------------- ------------------------------------------- -----------------------------------------------
  *COMT* ^158^Val/Val genotype vs. any Met allele                                               
  Episodic memory                                   −0.05 (−0.25‐0.15)                          .598
  Working memory                                    −0.14 (−0.53‐0.25)                          .482
  Attention                                         −0.18 (−0.20‐0.56)                          .350
  Executive function                                −0.19 (−0.51‐0.13)                          .245
  Visuospatial function                             −0.20 (−0.62‐0.22)                          .343
  *DRD2* ^957^T/T genotype vs. any C allele                                                     
  Episodic memory                                   −0.25 (−0.43 to −0.07)                      .007[a](#ane12812-note-0011){ref-type="fn"}
  Free recall                                       −0.42 (−0.78 to −0.07)                      .021[a](#ane12812-note-0011){ref-type="fn"}
  Cued recall                                       0.36 (0.04‐0.67)                            .026[a](#ane12812-note-0011){ref-type="fn"}
  Working memory                                    −0.33 (−0.69‐0.01)                          .060
  Attention                                         −0.58 (−0.91 to −0.26)                      \<.001[a](#ane12812-note-0011){ref-type="fn"}
  Executive function                                −0.31 (−0.61 to −0.02)                      .034
  Visuospatial function                             −0.38 (−0.75 to −0.01)                      .044

  Cerebrospinal fluid NFL concentration             Difference, ng/L (95% CI)   *P*‐value
  ------------------------------------------------- --------------------------- -----------
  *COMT* ^158^Val/Val genotype vs. any Met allele   3.8 (−433.0‐440.7)          .986
  *DRD2* ^957^T/T genotype vs. any C allele         265.2 (−125.7‐656.1)        .181

Fixed effects estimates for differences at 0, 1, 3, 5, and 8 years (for NFL concentration at 0, 1, and 3 years), after correction for age, sex, disease duration, time of testing, and years of education.

Significant (*P* \< 0.05) after Holm‐Bonferroni correction.

COMT, catechol‐O‐methyltransferase; DRD2, dopamine receptor D2; SD, standard deviation; NFL, neurofilament light chain protein.
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In the group of healthy control participants, *DRD2* ^957^T/T carriers performed poorer in tests of attention at an uncorrected statistical threshold (on average 0.47 standard deviations lower scores, *P* = .031, after correction for age, sex, time of testing, and years of education), similar to the performance in patients with PD. The difference was, however, non‐significant corrected for multiple comparisons.

4. DISCUSSION {#ane12812-sec-0014}
=============

By prospectively following a population‐representative cohort of patients with PD with neuropsychological evaluations for up to 10 years, we found that two common, functional polymorphisms in genes related to dopamine transmission (the *COMT* and *DRD2* genes), affect the evolution of cognitive deficits, and alter the risks of MCI and PDD.

Biomarkers predictive of cognitive dysfunction in idiopathic PD are of value because of the serious impact of such complications. Furthermore, common variations in genes with known biological effects have been favored as a mean to test causality of disease mechanisms in observational studies.[22](#ane12812-bib-0022){ref-type="ref"} The present study extends earlier observations of a relationship between frontostriatally based cognitive functions and genes associated with dopamine transmission and is, to our knowledge, the first to demonstrate the *DRD2* ^957^T/T genotype as a risk factor for PDD. The observed effects were not explained by differences in demographic factors such as age or by differences in medication.

Converging evidence points to a multifactorial etiology of cognitive dysfunction in PD. Patients with early PD underrecruit an extensive frontostriatal brain network as a consequence of dopaminergic hypofunction,[23](#ane12812-bib-0023){ref-type="ref"} contributing to cognitive impairments. In later disease phases, accumulating cortical Lewy bodies, Alzheimer disease‐type brain pathology and hypofunction in non‐dopaminergic (ie, acetylcholinergic) transmitter systems contribute to PD dementia (PDD).[24](#ane12812-bib-0024){ref-type="ref"} According to the "dual syndrome hypothesis," the early, dopamine dysfunction‐related impairments of frontostriatal, executive functions in PD are stable and do not strongly relate to dementia, while the more "posterior" deficits in visuospatial function or memory relate to cortical pathology that is predictive of PDD.[25](#ane12812-bib-0025){ref-type="ref"} The present findings potentially modify this hypothesis. In particular, the finding of *DRD2* ^957^T/T genotype as a risk factor for dementia (with the strongest detrimental effects seen in attention and episodic memory) suggests that dopamine hypofunction in PD may have effects beyond "frontostriatal" brain functioning including, possibly, alterations of distributed, dopamine‐dependent attention‐ and/or memory networks.

In healthy subjects, the high‐activity *COMT* ^158^Val‐allele has generally been found to impair executive functions such as working memory and cognitive flexibility.[26](#ane12812-bib-0026){ref-type="ref"}, [27](#ane12812-bib-0027){ref-type="ref"} In PD, studies by Williams‐Gray et al. showed that in later disease phases (\>1.6 years after diagnosis), the Val‐allele correlated with impairments in executive functioning (as measured by the "Tower of London" test), similar to findings in controls, while in early disease (\<1.6 years after diagnosis), the effect was opposite.[4](#ane12812-bib-0004){ref-type="ref"}, [28](#ane12812-bib-0028){ref-type="ref"} This was suggested to result from an inverted U‐shaped relation between cortical dopamine levels and prefrontal function, where a transient up‐regulation of prefrontal dopamine would cause "overdosing" in Met‐carriers in early PD, while the same patients would have an advantage in later disease phases, when progressive degeneration of dopaminergic systems produce more marked dopamine deficits. The present finding of mild cognitive impairments (MCI, as diagnosed according to the Movement Disorder Society) in *COMT* ^158^Val/Val carriers with PD could relate to the fact that the mean age at baseline was higher than in the CamPaIGN cohort, possibly making the studied population more vulnerable to a high prefrontal dopamine clearance. The invariably detrimental effect of the ^158^Val/Val genotype on cognition in the present study is also compatible with structural effects in the brain, for example an increased gray matter atrophy in dopamine‐innervated areas, such as reported in previous studies.[9](#ane12812-bib-0009){ref-type="ref"}

In relation to DRD2 function, patients with PD often experience memory problems characterized by an inability to recall information. This may partly relate to dopamine deficiency. The hippocampus is strongly interconnected with dopaminergic neurons in the midbrain,[29](#ane12812-bib-0029){ref-type="ref"} and several lines of evidence have established the importance of D2 receptor function in attention and memory.[30](#ane12812-bib-0030){ref-type="ref"} Specifically, the DRD2 system is linked to transient memory updating processes.[31](#ane12812-bib-0031){ref-type="ref"}, [32](#ane12812-bib-0032){ref-type="ref"} A reduction in D2 receptors has been found in PD[13](#ane12812-bib-0013){ref-type="ref"} and in imaging studies, memory deficits in PD are correlated with reduced extrastriatal D2 receptor binding in the medial temporal lobe, including the insula, in parts of the so‐called salience network.[14](#ane12812-bib-0014){ref-type="ref"} The present findings of poorer performances in attention and episodic memory and an increased risk of dementia in *DRD2* ^957^T/T carriers with PD could, potentially, relate to reduced function or increased vulnerability in D2‐dependent "salience networks" of the brain (eg, in medial, temporal structures). In this respect, the opposite effect on episodic memory in free recall compared to cued recall, related to the *DRD2* ^957^T/T genotype, is intriguing. This might suggest that the typical memory impairment in PD (memory deficits that improve with external cues) is a hypodopaminergic trait, specifically related to reduced function in D2 receptor signaling. This would be consistent with the proposed role of D2 receptors in flexible memory updating, and the corresponding memory deficit could gradually become more detrimental in PD compared to effects induced by COMT enzyme heterogeneity (related to the *COMT* Val^158^Met polymorphism).

Interestingly, the *DRD2* ^957^C/C genotype (and the *DRD2* gene locus) has previously been found to be associated to susceptibility to schizophrenia in younger populations.[33](#ane12812-bib-0033){ref-type="ref"}, [34](#ane12812-bib-0034){ref-type="ref"} The seemingly opposite effects of the *DRD2* ^957^C allele in different populations (increasing the risk of schizophrenia in young populations, while protecting against cognitive decline in PD) may be an example of genetic pleiotropism. The precise mechanisms behind the *DRD2*‐genotype‐induced effects on cognition were not determined by this study but merits further investigation.

While the effects on cognition were different for the *COMT* and *DRD2* genotypes, none of the genotypes affected cerebrospinal fluid NFL concentration (which has been found predictive of PDD).[35](#ane12812-bib-0035){ref-type="ref"} This suggests that the *COMT* and *DRD2* genotypes did not affect cognition through gross effects on neurodegeneration, at least not as measured by injury of myelinated axons. This is consistent with the trend of a similarly poorer performance in tests of attention in the healthy control persons with a *DRD2* ^957^T/T genotype, which may indicate that the *DRD2* genotype‐related effect on attention is not specific to degenerating dopaminergic systems, but rather is an effect on functions common to both disease‐affected and normal brains. The effect may, however, be amplified in PD. It could also be of interest to investigate the studied genotypes in Lewy Body Dementia.

A limitation was the small number of healthy controls and patients and the theoretical classification of cognitive tests in cognitive domains, which is, however, not standardized in clinical research settings. Our study also has strengths, namely a population‐based and longitudinal design, evaluation of incident cases, and the use of an extensive neuropsychological test battery at several times during the follow‐up period. The risk of incorrect PD diagnosis was minimized by the long follow‐up periods, the finding of pathologic uptake on DAT‐scan examination in all (100%) of the examined patients with PD, and by confirmation of the diagnosis by autopsy in a small number of cases.

In conclusion, although confirmation in independent, larger studies is needed, our results suggest that the *COMT* ^158^Val/Val genotype (which is known to produce a decrease in synaptic dopamine availability) increases the risk of MCI in PD and that the *DRD2* ^957^T/T genotype is a risk factor for PDD. These findings provide new insights into the mechanisms of cognitive dysfunction in PD. In the clinical setting, the *DRD2* ^957^T/T genotype could possibly be used as a marker for PDD risk.
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